Published online Jul 15, 2003. doi: 10.3748/wjg.v9.i7.1474
Revised: December 4, 2002
Accepted: December 7, 2002
Published online: July 15, 2003
AIM: To study the antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice
METHODS: The cytotoxicity of peritoneal macrophages (MΦ) against H22 cells was measured by the radioactivity of [3H]TdR assay, mice with H22 tumor were injected with different concentrations of resveratrol, and the inhibitory rates were calculated and IgG contents were determined by single immunodiffusion method. the plaque forming cell (PFC) was measured by improved Cunningham method, the levels of serum tumor necrosis factor-α (TNF-α) were measured by cytotoxic assay against L929 cells.
RESULTS: Resveratrol 2.5 mg•l-1, 5.0 mg•l-1, 10.0 mg•l-1, 20.0 mg•l-1 (E:T = 10:1, 20:1) promoted the cytotoxicity of MΦagainst H22 cells. Resveratrol ip 500 mg•kg-1, 1000 mg•kg-1 and 1500 mg•kg-1 could curb the growth of the implanted tumor of H22 in mice. The inhibitory rates were 31.5%, 45.6% and 48.7%, respectively (P < 0.05), which could raise the level of serum IgG and PFC response to sheep red blood cell. Resveratrol 1000 mg•kg-1 and 1500 mg•kg-1 and BCG 200 mg•kg-1 ip could increase the production of serum TNF-α in mice H22 tumor. However, the effect of resveratrol was insignificant (P > 0.05).
CONCLUSION: Resveratrol could inhibit the growth of H22 tumor in Balb/c mice. The antitumor effect of resveratrol might be related to directly inhibiting the growth of H22 cells and indirectly inhibiting its potential effect on nonspecific host immunomodulatory activity.